Cambridge Cognition Limited
Cambridge Cognition is the leading global provider of cognitive assessment software for use in clinical trials, academic research and healthcare provision - advancing research, diagnosis and treatment in mental health worldwide.
|Address:||Turnbridge Court, Turnbridge Lane, Bottisham|
Cambridge Cognition is the leading provider of cognitive assessment software for academic research, healthcare provision and clinical trials. Developing global solutions to improve mental wellbeing.
Our cognitive assessment software, powered by Cantab technology, has been highly validated by over 1,200 peer-review publications.
Cantab touchscreen neuropsychological tests are used by:
- Academic researchers in studies of cognition
- Clinical researchers in the pharmaceutical industry, to further knowledge of cognitive function
- Physicians to improve the monitoring, management and maintenance of cognitive health and wellbeing.
Our product ranges include:
Cambridge Cognition shows its groundbreaking mental health wearable Cognition Kit™ for the first time at the Neurotech Investing Conference in Boston this week.
7 April 2016Read in full
Cambridge Cognition Holdings plc, a specialist in the development and marketing of computerised tests for detection and monitoring of neuropsychological disorders, is pleased to announce that it has made significant progress with its commercial operations and expects to end the year with three new major pharmaceutical clinical trial contracts totalling US$4.5m.
24 November 2015Read in full
Three decades ago two emerging neuroscientists, Barbara Sahakian and Trevor Robbins from University of Cambridge, received a grant to fund their development of the Cambridge Neuropsychological Automated Test Battery or CANTAB™.
9 October 2015Read in full
Reliable cognitive measures for patients with Alzheimer's disease are essential when testing potential new drug interventions. The high attrition rate in Alzheimer’s disease clinical trials highlights the need for more sensitive analytical tools to be used throughout the drug development process.
21 May 2015Read in full
Cambridge Cognition today announces that sales of its Cantab Connect CTIS-Abuse Liability have exceeded £1 million ($1.5 million) in its first nine months from launch.
14 April 2015Read in full
Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the acceleration of safe and effective medicines in drug development, announces that it has now signed contracts with various leading pharmaceutical companies for eight human abuse and liability studies worth a total of approximately £710,000.
27 June 2014Read in full
Cambridge Cognition has announced the launch of the first two iPad-tablet products on its new cloud computing Cantab Connect platform for use in clinical trials. Rapid iPad assessment paves the way for faster and more accurate decision making on cognitive safety and abuse potential of drug treatments.
4 June 2014Read in full
Cambridge Cognition, the leading British developer of computerised neuropsychological tests, has floated on London’s Alternative Investment Market (AIM). The listing, which took place yesterday (Thurs), raised £5million. Shareholders realised a further £1.4m through the sale of existing Ordinary Shares.
19 April 2013Read in full
This is a great opportunity to join our team in Cambridge, UK. In this full-time role you will provide administration support to...
Location: Within 10 m of Cambridge